Portland Global Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 5.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,093 shares of the company’s stock after selling 508 shares during the quarter. Portland Global Advisors LLC’s holdings in Johnson & Johnson were worth $1,270,000 at the end of the most recent quarter.
A number of other institutional investors also recently added to or reduced their stakes in the business. Enterprise Financial Services Corp raised its stake in Johnson & Johnson by 2.4% during the fourth quarter. Enterprise Financial Services Corp now owns 15,075 shares of the company’s stock worth $2,106,000 after acquiring an additional 358 shares in the last quarter. NewFocus Financial Group LLC raised its stake in Johnson & Johnson by 1.1% during the third quarter. NewFocus Financial Group LLC now owns 32,795 shares of the company’s stock worth $4,264,000 after acquiring an additional 365 shares in the last quarter. Traynor Capital Management Inc. raised its stake in Johnson & Johnson by 3.5% during the third quarter. Traynor Capital Management Inc. now owns 10,822 shares of the company’s stock worth $1,401,000 after acquiring an additional 368 shares in the last quarter. Welch Investments LLC raised its stake in Johnson & Johnson by 1.0% during the fourth quarter. Welch Investments LLC now owns 35,981 shares of the company’s stock worth $5,027,000 after acquiring an additional 373 shares in the last quarter. Finally, YHB Investment Advisors Inc. raised its stake in Johnson & Johnson by 0.5% during the fourth quarter. YHB Investment Advisors Inc. now owns 76,534 shares of the company’s stock worth $10,693,000 after acquiring an additional 381 shares in the last quarter. Hedge funds and other institutional investors own 67.40% of the company’s stock.
Shares of JNJ stock opened at $123.85 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.58 and a quick ratio of 1.25. The stock has a market capitalization of $336.30 billion, a P/E ratio of 16.97, a PEG ratio of 1.92 and a beta of 0.74. Johnson & Johnson has a 12 month low of $125.00 and a 12 month high of $125.73.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The firm had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a return on equity of 30.65% and a net margin of 1.58%. The company’s revenue was up 12.6% on a year-over-year basis. During the same period last year, the company earned $1.83 earnings per share. equities analysts anticipate that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th will be given a $0.90 dividend. This represents a $3.60 dividend on an annualized basis and a yield of 2.91%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date is Friday, May 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.03%.
Several research analysts have issued reports on JNJ shares. Jefferies Group set a $165.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday, February 26th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a research note on Tuesday, January 23rd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $143.00 price objective for the company in a research note on Wednesday, March 28th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, April 17th. Finally, Deutsche Bank restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, April 18th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $142.23.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.